Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedVersion tag updated from v3.5.3 to v3.5.4, indicating a new release of the page. It represents an update to the page's metadata rather than a substantive change to the study information.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.5.3 is now displayed, replacing Revision: v3.5.2 on the page. This indicates a software update to the underlying component, with no changes to study content.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded a new revision tag 'Revision: v3.5.2' and removed the older tag 'Revision: v3.5.0'.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a new publication to the Publications section: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475.SummaryDifference0.1%

- Check74 days agoChange DetectedHepatocellular carcinoma has been added as the condition and the Genetic and Rare Diseases Information Center has been added to the resources. The page revision has been updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.2%

- Check81 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.